Fora Capital, LLC Mirati Therapeutics, Inc. Transaction History

Fora Capital, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $129,770 - $211,693	4,668 New	4,668 $203,000
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $304,045 - $443,037	5,110 New	5,110 $357,000
Q2 2022 Aug 11, 2022	SELL	$39.16 - $88.71 $178,961 - $405,404	-4,570 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$75.82 - $150.97 $137,082 - $272,953	1,808 Added 65.46%	4,570 $380,000
Q4 2021 Feb 11, 2022	BUY	$132.01 - $190.29 $364,611 - $525,580	2,762 New	2,762 $405,000

Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $164,105 - $220,392	-1,242 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $178,848 - $223,224	1,242 New	1,242 $201 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $690,825 - $963,338	-4,347 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $401,073 - $594,668	2,475 Added 132.21%	4,347 $954,000
Q3 2020 Nov 13, 2020	SELL	$113.26 - $167.27 $524,620 - $774,794	-4,632 Reduced 71.22%	1,872 $311 Million
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $468,353 - $783,016	6,504 New	6,504 $743 Million
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $280,166 - $466,583	-4,015 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $284,101 - $517,372	4,015 New	4,015 $517,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.